Core Viewpoint - Pfizer (NYSE: PFE) is currently trading below $30 per share, presenting a potential investment opportunity despite recent financial challenges [1]. Financial Performance - Pfizer's financial performance has been declining in recent years and is expected to continue this trend through 2028 due to the loss of patent exclusivity for key products, including the anticoagulant Eliquis [3]. - The company anticipates revenue declines in certain years as it navigates these challenges, indicating that it is not yet out of difficult times [3]. Growth Potential - Despite weak revenue and earnings growth projections, Pfizer could see significant share price increases due to advancements in its clinical and regulatory programs over the next three years [4]. - Investors are encouraged to consider initiating positions now, as the potential for upside may diminish if they wait for substantial improvements in financial results [4]. Promising Candidates - Two promising candidates that could significantly impact Pfizer's future are MET-097i, an investigational weight loss medicine with a favorable tolerability profile, and PF-4404, which is being explored for multiple cancer types [5][6]. - The weight loss market is rapidly expanding, making MET-097i a potentially important asset for Pfizer, while PF-4404 could lead to multiple indications, enhancing the company's growth prospects [6].

Industry Overview - The biotech and drug industry experienced a significant rebound in 2025 after a cautious start, driven by drug pricing agreements and increased M&A activity [1] - The FDA approved 44 novel therapies in 2025, with 26 approvals occurring in the second half of the year, indicating an acceleration in regulatory activity [1][2] Company Analysis: Altimmune (ALT) - Altimmune is focused on developing therapies for liver diseases, with its lead candidate pemvidutide currently in mid-stage studies for metabolic dysfunction-associated steatohepatitis (MASH) [4] - Shares of Altimmune have decreased over 46% year-to-date due to mixed results from the phase IIb IMPACT study, although it met one primary endpoint related to MASH resolution [5] - Recent 48-week results from the IMPACT study showed further improvements in non-invasive tests and significant reductions in liver health biomarkers [6] - Altimmune plans to initiate a late-stage study for pemvidutide in MASH in 2026 after aligning with the FDA on key parameters [7] - The company is also exploring pemvidutide for alcohol use disorder and alcohol-associated liver disease, with data expected next year [8] Company Analysis: ImmunityBio (IBRX) - ImmunityBio focuses on therapies for cancer and infectious diseases, with its marketed drug Anktiva approved for bladder cancer [11] - Shares of ImmunityBio have declined over 16% this year due to a regulatory setback from the FDA regarding a label expansion for Anktiva [12] - Despite the setback, Anktiva generated nearly $75 million in sales this year, a significant increase from $7 million in the previous year, and the company is seeking EU market expansion [13] - ImmunityBio is also developing Anktiva for other cancer indications, with promising data in non-small cell lung cancer and glioblastoma expected to be updated in 2026 [14] - Loss per share estimates for 2026 have improved from $0.37 to $0.33 in the past 60 days [15] Company Analysis: Seres Therapeutics (MCRB) - Seres Therapeutics is developing SER-155, an oral live biotherapeutic aimed at preventing bloodstream infections in patients undergoing stem cell transplantation [16] - Investor interest in SER-155 increased after a phase Ib study showed a 77% relative reduction in bacterial infections compared to placebo [17] - The FDA has provided positive feedback for SER-155's advancement to mid-stage development, with an interim update expected within 12 months of study initiation [18] - Shares of Seres Therapeutics have decreased nearly 12% year-to-date, but loss per share estimates for 2026 have improved from $10.66 to $7.67 in the past 60 days [18]